

Pharmacogenomics of antidepressant drugs: perspectives for the personalization of treatment in depression

Citation for published version (APA):

Fabbri, C. (2018). *Pharmacogenomics of antidepressant drugs: perspectives for the personalization of treatment in depression: Genetic biomarkers of drug treatment outcomes in depression*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20181114cf>

Document status and date:

Published: 01/01/2018

DOI:

[10.26481/dis.20181114cf](https://doi.org/10.26481/dis.20181114cf)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

**PHARMACOGENOMICS OF ANTIDEPRESSANT DRUGS: PERSPECTIVES
FOR THE PERSONALIZATION OF TREATMENT IN DEPRESSION**

Chiara Fabbri

SUMMARY

Depressive disorders affect more than 300 million people globally and are the third cause of disability worldwide. Genetic variants were demonstrated to explain a relevant proportion of variance in antidepressant response. The aim of this dissertation was to contribute to the identification of genetic markers that can be used to develop personalized antidepressant treatments, improving disease prognosis.

Different strategies were combined to achieve this purpose. Candidate genes implicated in antidepressant metabolism (cytochrome 2C19 or CYP2C19) or pharmacodynamics (e.g. FKBP5, CHL1) were investigated in terms of individual effect on treatment outcomes but also in terms of the molecular pathways through which they may play a role in antidepressant action. In addition to pathway analysis, the role of exomic variants as predictors and treatment-resistant depression (TRD) as phenotype were considered particularly promising since they were overlooked in previous studies.

Few candidate genes show potential clinical usefulness to guide antidepressant treatment when considered individually and CYP2C19 is one of these genes. Pathway analysis provides the potential of explaining a higher variance in outcomes than the study of single genes and help in clarifying the mechanisms of antidepressant action. The involved pathways include those mediating inflammation (e.g. B-cell receptor and steroid hormone signaling), neural plasticity and neurogenesis (e.g. regulation of chromatin structure). The inclusion of both common and rare variants in pathway analysis may allow the detection of signals that would be otherwise missed.

Current clinical applications of antidepressant pharmacogenetics are based on single candidate genes only. The current frontier is to develop polygenic predictors that can have a higher effect size compared to single genes as well as develop predictors of specific phenotypes such as TRD. This dissertation identified pathways that can be the starting point for further pharmacogenetic studies but can also serve to identify new pharmacological targets.